Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series D raises $60mm for Biolex to support Locteron trials

Executive Summary

Protein and antibody developer Biolex Therapeutics raised $60mm in its Series D financing led by new investor Clarus Ventures. First-time backer OrbiMed Advisors was joined by returning shareholders Intersouth Partners, Quaker BioVentures, Johnson & Johnson Development Corp., Investor Growth Capital, Polaris Ventures, Mitsui & Co. Ltd., Dow Chemical Co., JP Morgan Securities, and the North Carolina Economic Development Fund. Biolex will use the money to complete Phase II and prepare for Phase III trials of Locteron, to which the company recently received full rights from co-development partner OctoPlus. Representatives from Clarus and OrbiMed will take seats on Biolex's board.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies